ETERNAL Blend Side Effects: What Is Reported, What Is Rare, and Who Should Avoid It

Serious adverse events are not commonly reported for ETERNAL's components, but the reporting system behind that statement is weaker for compounded medications than for approved drugs, so treat it as reassuring rather than conclusive.

ETERNAL is four peptides dissolved together in one 5 mL vial: 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg epithalon. Pepti's typical directions are 0.25 mL, which is 25 units on a U-100 insulin syringe, under the skin once daily Monday through Friday, so each dose delivers 2.5 mg GHK-Cu and 0.5 mg of each of the other three. Your physician sets your directions after reviewing your intake, and they are printed on the vial. The arithmetic is in ETERNAL blend dosage.

There is no side-effect data for the four together, because the blend has never been studied as a blend. What follows is what is reported clinically and what the component pages describe. The three repair components are also the whole of GLOW, so GLOW side effects covers them in more depth; epithalon has its own page, epithalon side effects.

Copper is essential in small amounts and harmful in excess, and the liver is the body's route for excreting it.

This pattern is not reported at prescribed GHK-Cu doses in people with normal copper handling. It belongs to identifiable people: anyone with Wilson's disease, anyone whose liver cannot excrete copper normally, and anyone unknowingly taking two copper-containing products at once. Every GHK-Cu blend carries a full GHK-Cu dose, so ETERNAL alongside GHK-Cu, GLOW, KLOW, RADIANCE, REVIVE or EUPHORIA doubles the copper. High-dose zinc competes with copper absorption, so your physician needs to know your zinc dose. Do not change your supplements on your own; tell your physician what you take.

If you think you may have taken too much, for example by drawing the wrong amount, call Poison Control at 1-800-222-1222 and message your care team. Do not skip, double or change a dose to compensate.

• Injection-site reactions that keep happening despite rotating sites.
• Nausea, light-headedness, headache, tiredness or drowsiness that has not settled after the first couple of weeks.
• Nausea that seems to follow each dose.
• Any change in your medications or supplements, especially blood thinners, zinc, or another product containing GHK-Cu.
• A new diagnosis, a pregnancy, or a planned surgery.
• A vial that looks different from the last one.

Your physician may revise your directions, change the product, or stop treatment. Do not change the dose yourself. When directions change, the new numbers are printed on the new label.

There is no established interaction list for ETERNAL or any component, because the trials that would produce one have not been run. That is why the intake asks for every medication and supplement you take.

• Side effects of the four together. ETERNAL has never been studied as a combination.
• Long-term human outcomes. No cohort has been followed for years on ETERNAL or any component by injection.
• Whether the cancer concern is real. It is mechanistic reasoning, not an observed human signal, and it has not been ruled out.
• Cumulative copper load from long-term injectable use. There is no published schedule for it.
• Subcutaneous pharmacokinetics in humans. The FDA found no human pharmacokinetic data for epithalon, and none is described for the other three by this route.

Each component is generally described as well tolerated in its own animal work, and clinical reports are consistent with that. For epithalon, the FDA's 2026 review found no clinical safety study, no formal toxicology and no adverse-event reports, which is an absence of data rather than evidence of safety. So the honest statement is narrow: short-term tolerability looks good where these components have been used, and long-term safety is not characterised. The separate and non-theoretical risk is supply: research-use-only blends are sold with no pharmacy accountable for what is in them. Research peptides vs prescription peptides sets out the difference.

All four components were removed from Category 2 in April 2026; BPC-157, TB-500 and epitalon were recommended for the 503A Bulks List by the advisory committee in July 2026, with final determinations pending; GHK-Cu is scheduled for review before the end of February 2027.

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with ice packs, with sterile syringes, alcohol prep pads and your directions printed on the vial.
5. Your physician stays reachable for questions and side effects.

ETERNAL is $279 a month, all-in, covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. Refills run every 28 days, one vial per fill. Pepti prescribes ETERNAL in every state except Oklahoma, plus DC The full reference is what is the ETERNAL blend.